Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
...AVEN, Conn., May 29 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...0, 2009. A copy of the poster will be available on
vion Pharmaceuticals' website, www.vionpharm.com , o...2:00 p.m. on Saturday, May 30, 2009.
About
vion
...
Vion Pharmaceuticals Reports 2009 First Quarter Results
...EW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...ilable through Thursday, May 28, 2009.
About
vion
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM)
... HAVEN, Conn., April 23 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...to have an FDA decision this year."
About
vion Pharmaceuticals
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Pharmaceuticals' New Drug Application for Onrigin(TM)Accepted For Review by the FDA
... HAVEN, Conn., April 16 /PRNewswire-FirstCall/ --
vion Pharmaceuticals, Inc. (OTC Bulletin Board: VION) ...rst indication in the United States."
About
vion Pharmaceuticals
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Updates Conference Call Information
...hrough Thursday, November 20, 2008.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Laromustine (Cl...al Cancer
Institute. For additional information on
vion and its product development
programs, visit the Co...
Vion Reports 2008 Third Quarter and Nine-Month Results
...hrough Thursday, November 20, 2008.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Laromustine (Cl...al Cancer
Institute. For additional information on
vion and its product development
programs, visit the Co...
Vion Reports 2008 Second Quarter and Six-Month Results
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced financial results for
the three-...
through Thursday, August 21, 2008.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
BeaconEquity.com Issues TraderNotes on Biotechnology Stocks: TPIM, RXII, VION, CUR, AMGN, GILD, BIIB, GENR
...nc. (OTC Bulletin Board: TPIM),
RXi Pharmaceuticals Corp. (Nasdaq: RXII ),
vion Pharmaceuticals Inc.
(Nasdaq:
vion ), Neuralstem Inc. (Amex: CUR ), Amgen Inc. (Nasdaq: AMGN ),
Gilead Scien...
Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that data from the
Phase III tri...presentation of the unblinded data.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Pharmaceuticals to Appeal Nasdaq Delisting
... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS,
INC. (Nasdaq:
vion ) today announced that it had received a letter, d...ant the Company's request for
continued listing.
vion Pharmaceuticals, Inc. is committed to extending th...
Vion in Medical Technology
Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
...nducted at
various sites in France.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Laromustine (Cl...al Cancer Institute. For additional information on
vion and its
product development programs, visit the Co...
Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
...s, Belgium, Switzerland and Norway.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Laromustine (Cl...al Cancer
Institute. For additional information on
vion and its product development
programs, visit the Co...
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that data from a
previously cond...g/m2 of
Cloretazine(R) (VNP40101M).
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that interim data from
the pivot...gy Annual Meeting in December 2007.
About Vion
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that data from two
clinical tria...1, 2008. A copy of the poster
will be available on
vion Pharmaceuticals' website, http://www.vionpharm.co...m E354a. A
copy of the poster will be available on
vion Pharmaceuticals' website,
http://www.vionpharm.co...
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
... NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS,
INC. (Nasdaq:
vion ) today announced the start of an investigator-spo... as
well as improve the quality of their lives."
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that the U.S. Food and
Drug Admi...ewers performed a
comprehensive safety analysis of
vion Study CLI-037. This analysis
concluded that the co...(R)) in
December 2007.
Conference Call Details
vion will hold a conference call on Tuesday, January 8,...
Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
...FirstCall/ -- Vion
Pharmaceuticals, Inc. (Nasdaq:
vion ) today announced that preliminary data
from its p... poster. A copy of the poster
will be available on
vion Pharmaceuticals' website, http://www.vionpharm.co... be available
through Monday, December 24, 2007.
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
...ntribution in the stem cell
transplant setting."
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...al Cancer
Institute. For additional information on
vion and its product development
programs, visit the Co...
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that an
investigator-sponsored t...of Clinical Oncology Annual Meeting in
June 2007.
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion in Biological Technology
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
...W HAVEN, Conn., Feb. 17 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...d, "This NDA filing is a significant milestone for
vion and for the Onrigin clinical development program. ...tions are needed for this population.
About
vion
...
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
...EW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) ...an Francisco from December 6-9, 2008.
vion Poster Presentation
The Company announc...
New Trade Name for Laromustine
vion will introduce Onrigin(TM) as the new trade name f...
Vion Reports 2008 First Quarter Results
... NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ --
vion PHARMACEUTICALS,
INC. (Nasdaq:
vion ) today announced financial results for the three-...ained herein are provided on a post-split basis.
vion Pharmaceuticals, Inc. is committed to extending th...
Vion Pharmaceuticals Files Plan With Nasdaq
...FirstCall/ -- Vion
Pharmaceuticals, Inc. (Nasdaq:
vion ) today announced that it had filed a
plan to achi...cision to a
Nasdaq Listing Qualifications Panel.
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Reports 2007 Fourth Quarter and Year-End Results
...ained herein are provided on a post-split basis.
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...nce of unanticipated events.
COMPANY CONTACT:
vion Pharmaceuticals, Inc. Alan Kess...
Vion Pharmaceuticals to Host Conference Call to Discuss 2007 Fourth Quarter and Year-End Financial Results
...ill be available through Tuesday,
April 1, 2008.
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...al Cancer Institute. For additional
information on
vion and its product development programs, visit the
Co...
Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that the Company would
implement...nesday, February 20, 2008.
On a pre-split basis,
vion Pharmaceuticals has 81,017,569 shares
outstanding ...ult of the reverse stock
split, every 10 shares of
vion Common Stock will be combined into one share
of...
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that the Company had
paid intere... interest was paid in lieu of fractional
shares.
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Pharmaceuticals Holds Special Meeting of Stockholders
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) announced that a Special Meeting of
Stockholders... compliance with Nasdaq's
listing requirements."
vion Pharmaceuticals, Inc. is committed to extending th...nd commercializing innovative cancer therapeutics.
vion has two agents in
clinical trials. Cloretazine(R) ...
Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
...FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq:
vion ) today announced that William Hahne,
M.D. has joi...e are extremely pleased
to have Bill Hahne joining
vion in medical affairs. He has a wealth of
experience ...ersity
Affiliated Hospitals in Atlanta, Georgia.
vion Pharmaceuticals, Inc. is committed to extending th...